Tapotoclax - CISMeF

Preferred Label : Tapotoclax;

NCIt definition : An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.;

UNII : 97W7N9T08G;

InChIKey : JQNINBDKGLWYMU-GEAQBIRJSA-N;

CAS number : 1883727-34-1;

Molecule name : AMG 176;

NCI Metathesaurus CUI : CL507931;

Détails

Origin ID

C127817;

UMLS CUI

C5418177;

Currated CISMeF NLP mapping
- tapotoclax [MeSH concept]
- tapotoclax [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- tapotoclax [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients